Autolomous and Cellular Origins reported end-to-end integration of their cell-therapy manufacturing platforms, targeting greater automation and digitization across the production workflow. The companies said the joint solution improves standardization, traceability, and real-time control without replacing existing bioprocessing steps. Cellular Origins brings its Constellation automated platform for sterile transfers and mobile robotics, while Autolomous contributes digital autoloMATE to coordinate data exchange across software, AI systems, and robotic devices. The integration has already been demonstrated at Cell and Gene Therapy Catapult Digital and Automation testbeds, and the companies tied the approach to faster scaling from research through patient administration. The development speaks directly to recurring constraints in cell and gene therapy output—especially workforce, variability, and operational visibility.